WIN-Partners Co., Ltd.

WIN-Partners Co., Ltd.

TTSE:3183
1,243.00
JPY
-12.00
(-0.96%)
73.70EPS
16.76P/E
33.96BMarket Cap
Feb 10Next Earn
WIN-Partners Co., Ltd.
TSE:3183
(Tokyo Stock Exchange)

Recent

price

1,243.00

P/E

ratio

16.76

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
111,700.57
1,218.66
1,189.08
1,349.47
1,389.52
1,886.12
2,011.97
2,188.65
2,430.51
2,248.06
2,163.98
2,315.28
2,493.14
2,703.63
2,847.52
3,153.84
3,333.38
Revenue per Share
3,260.24
36.67
34.71
39.12
39.34
73.56
74.58
104.69
91.99
65.23
53.66
63.88
72.04
64.4
70.62
73.91
73.7
Basic EPS, GAAP
3,239.55
67.73
18.93
15.3
60.46
71.72
113.54
39.88
76.58
108.39
23.47
-4.77
-18.48
89.14
55.79
94.33
- -
Free Cash Flow per Basic Share
927.52
8.2
13
12.59
14
19
20.5
26
29
32
33
34.04
35
49.85
49.95
51.87
- -
Dividend per Share
220.82
250.4
271.24
297.44
324.52
485.15
539.69
618.79
680.89
714.27
736.32
764.32
801.64
818.75
841.88
846.95
807.35
Book Value per Share
213.62
245.18
267.35
292.42
315.13
477.81
534.12
614.34
677.17
710.28
731.83
758.82
788.56
805.59
827.84
812.81
769.47
Tangible Book Value per Share
- -
25
25
24
24
29
29
29
29
29
29
29
28
29
29
29
28
Basic Weighted Avg Shares
28,127
29,987
29,259
32,957
33,913
54,147
57,760
62,832
69,776
64,538
62,124
66,392
70,854
77,064
81,410
90,392
92,277
Sales/Revenue/Turnover
4.58
5.14
4.95
5
4.59
5.48
5.3
5
4.67
4.11
3.63
4.16
3.49
3.41
3.45
3.34
3.16
Operating Margin (%)
130
108
136
182
167
277
249
262
237
196
194
161
166
196
232
300
- -
Depreciation Expense
821
902
854
955
960
2,112
2,141
3,006
2,641
1,873
1,541
1,832
2,047
1,836
2,019
2,118
2,040
Net Income, GAAP
41.68
41.74
41.63
42.36
38.7
31.67
30.2
21.46
25.4
31.26
31.41
31
30.48
32.52
29.52
31.32
31.77
Effective Tax Rate (%)
2.92
3.01
2.92
2.9
2.83
3.9
3.71
4.78
3.78
2.9
2.48
2.76
2.89
2.38
2.48
2.34
2.21
Profit Margin (%)
4,107
4,720
5,178
5,720
5,788
11,721
13,431
15,399
17,315
18,402
18,034
16,047
18,788
19,014
18,339
17,617
16,264
Working Capital
193
114
41
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
713
- -
LT Debt
5,434
6,162
6,674
7,259
7,920
13,928
15,494
17,764
19,547
20,506
21,138
21,722
22,782
23,385
24,069
23,290
22,201
Total Equity
8.81
10.11
9.25
9.85
9.07
15.95
13.99
14.43
12.71
8.89
7.3
8.72
7.54
7.53
8.17
8.41
8.9
Return on Invested Capital (%)
10.21
10.66
9.75
10.34
9.52
17.31
14.55
18.07
14.16
9.35
7.4
8.55
9.2
7.95
8.51
8.81
9.23
Return on Capital (%)
15.63
15.56
13.31
13.71
12.65
19.33
14.55
18.07
14.16
9.35
7.4
8.55
9.2
7.95
8.51
8.95
9.23
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
713
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
27
27
27
Market Capitalization
36,903
37,646
33,961

Working Capital

JPY

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
41,599
42,862
41,741
Cash, Cash Equivalents & STI
14,890
15,932
15,001
Accounts Receivable, Net
17,005
18,526
17,886
Inventories
3,702
3,922
4,465
Total Current Liabilities
23,338
25,245
25,477
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.39%
1.99%
-3.24%
Free Cash Flow
-33.96%
-77.65%
69.51%
Net Income, GAAP
1.81%
7.05%
4.92%
Sales/Revenue/Turnover
5.43%
7.8%
11.03%
Total Cash Common Dividend
11.21%
10.48%
4.1%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
19,604
19,349
21,486
20,971
81,410
2026
22,086
21,653
22,538
24,115
90,392
2027
23,971
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
13.89
15.74
19.66
21.16
70.62
2026
16.98
19.15
18.58
21.3
73.91
2027
14.64
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
49.95
2026
- -
- -
- -
- -
51.87
2027
- -
- -
- -
- -
- -
Business
WIN-Partners Co., Ltd. WIN-Partners Co., Ltd. (3183.T) operates as a holding company that, through its subsidiaries, distributes medical devices primarily to medical institutions across Japan. The company specializes in minimally invasive treatment products, particularly in cardiovascular applications, where it holds the largest market share for percutaneous coronary intervention (PCI) devices used in myocardial infarction and angina pectoris treatments; its core offerings include PTCA balloon catheters, drug-eluting stents (DES), and intravascular ultrasound (IVUS) catheters for PCI, pacemakers, implantable cardioverter defibrillators (ICD), cardiac resynchronization therapy defibrillators (CRTD), and ablation (ABL) catheters for the cardiac rhythm segment (CRS), stent grafts, transcatheter heart valves, and mechanical heart valves for the cardiac vascular segment (CVS), peripheral vascular stents, carotid artery stents, and embolic coils for percutaneous peripheral intervention (PPI) and neurovascular applications, as well as insulin pumps, continuous glucose monitoring (CGM) systems for the diabetes mellitus segment (DMS), and large-scale equipment such as computed tomography (CT) scanners. Approximately 67% of group sales derive from heart treatment-related products in fiscal year 2025, with expansion into non-cardiac areas including peripheral vascular disease, neurosurgery, and diabetes; operations focus on the Japanese market, serving hospitals and clinics through an extensive sales network headquartered at Kyobashi Edogrand in Tokyo, where the company was established on April 1, 2013, as a merger of WIN INTERNATIONAL and TESCO. Recent developments include TESCO's acquisition of TOSAY Medical, a major medical device distributor in Iwate Prefecture, in August 2022 to broaden regional coverage, alongside the company's transition to the Tokyo Stock Exchange Prime Market in April 2022; in June 2025, Office A Ltd. acquired over 5% of WIN-Partners' voting rights as a strategic long-term shareholder move equivalent to a tender offer. Subsidiaries such as TESCO, formerly including TESCO Akita (from Osawa Shoji acquisition in 2017) and MCI (from 2018 acquisition), support nationwide distribution of these specialized devices targeting cardiologists, vascular surgeons, and other minimally invasive specialists.